Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison.

The dose of toxicant reaching the embryo is a critical determinant of developmental toxicity, and is likely to be a key factor responsible for interspecies variability in response to many test agents. This review compares the mechanisms regulating disposition of toxicants from the maternal circulation to the embryo during organogenesis in humans and the two species used predominantly in regulatory developmental toxicity testing, rats and rabbits. These three species utilize fundamentally different strategies for maternal-embryonic exchange during early pregnancy. Early postimplantation rat embryos rely on the inverted visceral yolk sac placenta, which is in intimate contact with the uterine epithelium and is equipped with an extensive repertoire of transport mechanisms, such as pinocytosis, endocytosis, and specific transporter proteins. Also, the rat yolk sac completely surrounds the embryo, such that the fluid-filled exocoelom survives through most of the period of organogenesis, and can concentrate compounds such as certain weak acids due to pH differences between maternal blood and exocelomic fluid. The early postimplantation rabbit conceptus differs from the rat in that the yolk sac is not closely apposed to the uterus during early organogenesis and does not completely enclose the embryo until relatively later in development (approximately GD13). This suggests that the early rabbit yolk sac might be a relatively inefficient transporter, a conclusion supported by limited data with ethylene glycol and one of its predominant metabolites, glycolic acid, given to GD9 rabbits. In humans, maternal-embryo exchange is thought to occur via the chorioallantoic placenta, although it has recently been conjectured that a supplemental route of transfer could occur via absorption into the yolk sac. Knowledge of the mechanisms underlying species-specific embryonic disposition, factored together with other pharmacokinetic characteristics of the test compound and knowledge of critical periods of susceptibility, can be used on a case-by-case basis to make more accurate extrapolations of test animal data to the human.

[1]  W. Jollie.  Development, morphology, and function of the yolk-sac placenta of laboratory rodents. , 1990, Teratology.

[2]  J. Lloyd,et al.  Lysosomal Enzyme Inhibition by Trypan Blue: A Theory of Teratogenesis , 1967, Science.

[3]  H. Nau,et al.  Serum Protein Binding of Valproic Acid in Fetus‐Mother Pairs Throughout Pregnancy: Correlation With Oxytocin Administration and Albumin and Free Fatty Acid Concentrations , 1986, Journal of clinical pharmacology.

[4]  J. Hustin,et al.  Maternal circulation in the first-trimester human placenta--myth or reality? , 1997, American journal of obstetrics and gynecology.

[5]  D. Nebert,et al.  The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. , 1979, Teratology.

[6]  John F. Young,et al.  Correlating pharmacokinetics and teratogenic endpoints. , 1983, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[7]  K. Otani,et al.  Placental transfer and neonatal elimination of mono-unsaturated metabolites of valproic acid. , 1987, British journal of clinical pharmacology.

[8]  H Nau,et al.  Species differences in pharmacokinetics and drug teratogenesis. , 1986, Environmental health perspectives.

[9]  M. Eadie,et al.  Transplacental transfer and biotransformation studies of valproic acid and its glucuronide(s) in the perfused human placenta. , 1989, The Journal of pharmacology and experimental therapeutics.

[10]  S. Pynnönen,et al.  Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. , 2009, Acta pharmacologica et toxicologica.

[11]  H. Wong,et al.  Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[12]  O Pelkonen,et al.  Carbamazepine and Its Metabolites in Human Perfused Placenta and in Maternal and Cord Blood , 1995, Epilepsia.

[13]  H. Nau,et al.  Low teratogenicity of 13-cis-retinoic acid (isotretinoin) in the mouse corresponds to low embryo concentrations during organogenesis: comparison to the all-trans isomer. , 1987, Toxicology and applied pharmacology.

[14]  James L. Schardein,et al.  Chemically Induced Birth Defects , 1985 .

[15]  J. Simpkins,et al.  Distribution of Phenobarbital and Phenytoin in Pregnant Rats and Their Fetuses , 1991, Epilepsia.

[16]  T. Blankenship,et al.  Comparative placental structure. , 1999, Advanced drug delivery reviews.

[17]  R. Dickinson,et al.  MATERNOFETAL TRANSFER OF PHENYTOIN, p‐HYDROXY‐PHENYTOIN AND p‐HYDROXY‐PHENYTOIN‐GLUCURONIDE IN THE PERFUSED HUMAN PLACENTA , 1989, Clinical and Experimental Pharmacology and Physiology.

[18]  Richard A Corley,et al.  Evaluation of Physiologically Based Models of Pregnancy and Lactation for Their Application in Children's Health Risk Assessments , 2003, Critical reviews in toxicology.

[19]  B. Schwetz,et al.  Species sensitivities and prediction of teratogenic potential. , 1985, Environmental health perspectives.

[20]  E. Jauniaux,et al.  Nutrition of the human fetus during the first trimester--a review. , 2001, Placenta.

[21]  E J O'Flaherty.  Physiologically based pharmacokinetic models in developmental toxicology. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[22]  H. Nau,et al.  Teratogenicity and placental transfer of all-trans-, 13-cis-, 4-oxo-all-trans-, and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. , 1989, Toxicology and applied pharmacology.

[23]  H. Nau,et al.  Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. , 1981, The Journal of pharmacology and experimental therapeutics.

[24]  H. Nau,et al.  Comparative teratology and transplacental pharmacokinetics of all-trans-retinoic acid, 13-cis-retinoic acid, and retinyl palmitate following daily administrations in rats. , 1994, Toxicology and applied pharmacology.

[25]  L. Bertilsson.  Clinical Pharmacokinetics of Carbamazepine , 1978, Clinical pharmacokinetics.

[26]  W. Collins,et al.  Relationship between protein concentrations in embryological fluids and maternal serum and yolk sac size during human early pregnancy. , 1994, Human reproduction.

[27]  H. Nau,et al.  Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers , 1980, European Journal of Clinical Pharmacology.

[28]  G. R. Cannell,et al.  DISPOSITION OF PHENYTOIN AND PHENOBARBITONE IN THE ISOLATED PERFUSED HUMAN PLACENTA , 1988, Clinical and experimental pharmacology & physiology.

[29]  H. Wong,et al.  Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  B. Mirkin.  Placental transfer and neonatal elimination of diphenylhydantoin. , 1971, American journal of obstetrics and gynecology.

[31]  P. Morselli,et al.  Placental transfer of carbamazepine in the rat , 1975, The Journal of pharmacy and pharmacology.

[32]  E W Carney,et al.  Evaluation of various toxicants in rabbit whole-embryo culture using a new morphologically-based evaluation system. , 1999, Teratology.

[33]  O. Svensmark,et al.  Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. , 1967, Lancet.

[34]  O. Pelkonen.  Biotransformation of xenobiotics in the fetus. , 1980, Pharmacology & therapeutics.

[35]  H. Nau,et al.  Anticonvulsants during Pregnancy and Lactation Transplacental, Maternal and Neonatal Pharmacokinetics , 1982, Clinical pharmacokinetics.

[36]  J. DeSesso,et al.  Lectin teratogenesis. II: Demonstration of increased binding of concanavalin A to limb buds of rabbit embryos during the teratogenically sensitive period. , 1989, Teratology.

[37]  R. Foote,et al.  The rabbit as a model for reproductive and developmental toxicity studies. , 2000, Reproductive toxicology.

[38]  E. O'flaherty.  Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities. , 1997, Reproductive toxicology.

[39]  H. Nau,et al.  Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. , 1984, The Journal of pediatrics.

[40]  N. Agnish,et al.  Teratogenicity and transplacental pharmacokinetics of 13-cis-retinoic acid in rabbits. , 1994, Toxicology and applied pharmacology.

[41]  Teissié,et al.  Electropermeabilization of cell membranes. , 1999, Advanced drug delivery reviews.

[42]  H. Nau,et al.  Teratogenicity of the 13-cis and all-trans-isomers of the aromatic retinoid etretin: correlation to transplacental pharmacokinetics in mice during organogenesis after a single oral dose. , 1990, Teratology.

[43]  L. Bertilsson,et al.  Disposition of placentally transferred carbamazepine (Tegretol®) in the newborn , 1975, European Journal of Clinical Pharmacology.

[44]  D. Varma.  Modification of transplacental distribution of salicylate in rats by acidosis and alkalosis , 1988, British journal of pharmacology.

[45]  P. Guittin,et al.  Changes in Clinical Pathology Parameters During Gestation in the New Zealand White Rabbit , 1999, Toxicologic pathology.

[46]  E. Jauniaux,et al.  Fluid compartments of the embryonic environment. , 2000, Human reproduction update.

[47]  G. Levy,et al.  Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium , 1975, Clinical pharmacology and therapeutics.

[48]  H. Nau,et al.  Maternal toxicokinetics, metabolism, and embryo exposure following a teratogenic dosing regimen with 13-cis-retinoic acid (isotretinoin) in the cynomolgus monkey. , 1994, Teratology.

[49]  J. Lloyd,et al.  The role of the visceral yolk sac in mediating protein utilization by rat embryos cultured in vitro. , 1981, Journal of embryology and experimental morphology.

[50]  G. Levy,et al.  Fetal acquisition and neonatal elimination of a large amount of salicylate , 1975, Clinical pharmacology and therapeutics.

[51]  Y Ohno,et al.  Effects of trypan blue on rat and rabbit embryos cultured in vitro. , 1993, Toxicology in vitro : an international journal published in association with BIBRA.

[52]  H. Nau,et al.  Developmental stage-associated differences in the transplacental distribution of 13-cis- and all-trans-retinoic acid as well as their glucuronides in rats and mice. , 1995, Toxicology and applied pharmacology.

[53]  N. Gerber,et al.  Transmission of valproic acid (Depakene) across the placenta: half-life of the drug in mother and baby. , 1979, The Journal of pediatrics.

[54]  A. Enders.  A COMPARATIVE STUDY OF THE FINE STRUCTURE OF THE TROPHOBLAST IN SEVERAL HEMOCHORIAL PLACENTAS. , 1965, The American journal of anatomy.

[55]  H. Nau,et al.  Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo , 1986, Nature.